Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCANDESARTAN CILEXETIL (candesartan cilexetil) by Viatris (2) is angiotensin-converting enzyme (ace, kininase ii). Approved for hypertension in adults, children 1 to <17 years of age, to lower blood pressure and 7 more indications. First approved in 2014.
Drug data last refreshed 19h ago
angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Candesartan blocks…
Worked on CANDESARTAN CILEXETIL at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil
Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions
Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions
Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo